BR0307303A - Processo para a fabricação de inibidores da hmg-coa redutase - Google Patents

Processo para a fabricação de inibidores da hmg-coa redutase

Info

Publication number
BR0307303A
BR0307303A BR0307303-3A BR0307303A BR0307303A BR 0307303 A BR0307303 A BR 0307303A BR 0307303 A BR0307303 A BR 0307303A BR 0307303 A BR0307303 A BR 0307303A
Authority
BR
Brazil
Prior art keywords
manufacture
hmg
coa reductase
reductase inhibitors
sub
Prior art date
Application number
BR0307303-3A
Other languages
English (en)
Inventor
Murat Acemoglu
Bernhard Riss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0307303A publication Critical patent/BR0307303A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

"PROCESSO PARA A FABRICAçãO DE INIBIDORES DA HMG-COA REDUTASE". A invenção refere-se a um processo para a fabricação de um composto de fórmula ou um sal, especialmente um sal farmaceuticamente aceitável com uma base, do mesmo ou uma lactona do mesmo em que o elemento <sym> representa -CH~ 2~-CH~ 2~- ou -CH=CH- e R representa um resíduo cíclico.
BR0307303-3A 2002-01-31 2003-01-30 Processo para a fabricação de inibidores da hmg-coa redutase BR0307303A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
PCT/EP2003/000954 WO2003064392A1 (en) 2002-01-31 2003-01-30 Process for the manufacture of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
BR0307303A true BR0307303A (pt) 2005-01-11

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307303-3A BR0307303A (pt) 2002-01-31 2003-01-30 Processo para a fabricação de inibidores da hmg-coa redutase

Country Status (23)

Country Link
US (2) US7371865B2 (pt)
EP (1) EP1472228B1 (pt)
JP (1) JP4524111B2 (pt)
KR (1) KR20040081161A (pt)
CN (1) CN1305853C (pt)
AT (1) ATE426594T1 (pt)
AU (1) AU2003226971B2 (pt)
BR (1) BR0307303A (pt)
CA (1) CA2472776C (pt)
CO (1) CO5601005A2 (pt)
DE (1) DE60326819D1 (pt)
EC (1) ECSP045214A (pt)
ES (1) ES2323267T3 (pt)
HK (1) HK1070651A1 (pt)
IL (1) IL162980A (pt)
MX (1) MXPA04007396A (pt)
NO (1) NO327091B1 (pt)
NZ (1) NZ534232A (pt)
PL (1) PL370658A1 (pt)
PT (1) PT1472228E (pt)
RU (1) RU2299196C2 (pt)
WO (1) WO2003064392A1 (pt)
ZA (1) ZA200405322B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142582A1 (en) 2003-02-12 2006-06-29 Van Der Schaaf Paul A Crystalline forms of pitavastatin calcium
DE602004028599D1 (de) * 2003-04-24 2010-09-23 Daicel Chem Verfahren zur herstellung von (3r,5s,6e)-7-ä2-cyclopropyl-4-(4-fluorphenyl)chinolin-3-ylü -3,5-dihydroxy-6-heptensäureethylester
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
WO2006035286A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
ES2564250T3 (es) * 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
SI2086945T1 (sl) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
WO2008130638A2 (en) * 2007-04-18 2008-10-30 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of hmg-coa reductase inhibitors
EP2178890A1 (en) * 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Purification of rosuvastatin intermediate by thin film evaporation and chemical method
US8487105B2 (en) * 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) * 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
WO2012002741A2 (en) * 2010-07-01 2012-01-05 Yuhan Corporation Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2013080219A2 (en) 2011-11-28 2013-06-06 Mylan Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
DE60136095D1 (de) * 2000-11-16 2008-11-20 Teva Pharma Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-heptansäureestern mit calciumhydroxid
KR100883874B1 (ko) * 2001-02-02 2009-02-17 미쯔비시 가가꾸 가부시끼가이샤 (3ｒ,5ｓ)-(ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법
KR100919941B1 (ko) * 2001-11-14 2009-10-05 닛산 가가쿠 고교 가부시키 가이샤 광학활성 옥소헵텐산 에스테르의 제조방법
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
PT1472228E (pt) 2009-06-24
DE60326819D1 (de) 2009-05-07
EP1472228B1 (en) 2009-03-25
HK1070651A1 (en) 2005-06-24
ES2323267T3 (es) 2009-07-10
EP1472228A1 (en) 2004-11-03
RU2004126442A (ru) 2005-06-10
ATE426594T1 (de) 2009-04-15
WO2003064392A1 (en) 2003-08-07
CN1305853C (zh) 2007-03-21
US7371865B2 (en) 2008-05-13
MXPA04007396A (es) 2004-10-11
JP2005520814A (ja) 2005-07-14
NZ534232A (en) 2006-03-31
NO327091B1 (no) 2009-04-20
US20050070605A1 (en) 2005-03-31
IL162980A (en) 2010-02-17
PL370658A1 (en) 2005-05-30
ECSP045214A (es) 2004-09-28
NO20043611L (no) 2004-08-30
CA2472776C (en) 2011-01-25
CA2472776A1 (en) 2003-08-07
ZA200405322B (en) 2005-07-27
CN1622937A (zh) 2005-06-01
US20080182873A1 (en) 2008-07-31
JP4524111B2 (ja) 2010-08-11
KR20040081161A (ko) 2004-09-20
CO5601005A2 (es) 2006-01-31
RU2299196C2 (ru) 2007-05-20
AU2003226971B2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1070651A1 (en) Process for the manufacture of hmg-coa reductase inhibitors
ECSP055913A (es) Inhibidores de las polimerasas víricas
EP2299508A3 (en) Organic photosensitive optoelectronic device having a phenanthroline exciton blocking layer
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
NO20062644L (no) DPP-IV inhibitorer
IL177537A (en) Viral polymerase inhibitors, and pharmacological compounds containing them
WO2006027711A3 (en) Prodrugs and codrugs containing bio- cleavable disulfide linkers
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
NO20062656L (no) Fremgangsmate for fremstilling av statiner
EP1975164A3 (en) Octahydrobenzimidazolone compounds as analgetics
HK1076816A1 (pt)
ATE511352T1 (de) Antimikrobielle zusammensetzungen
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
SE0000933D0 (sv) Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds
MXPA04000357A (es) COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA.
EA200300804A1 (ru) Усовершенствованный способ получения карбапенема
MY138826A (en) 2,7-substituted indoles
ATE516031T1 (de) Verbindungen gegen krebs
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
DE60114640D1 (en) Antithrombosemittel
EP2266971A3 (en) Hiv protease inhibiting compounds
MY129094A (en) Condensed polycyclic compounds
EP1253139A3 (en) Multioligoanilinated fullerenes

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 215/14, C07D 405/06, C07D 209/18, C07B 53/00, A61P 3/06, A61P 43/00, A61P 9/10

Ipc: C07D 215/14 (2011.01), C07D 405/06 (2011.01), C07D

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.